View Financial HealthInnoviva 配当と自社株買い配当金 基準チェック /06Innoviva現在配当金を支払っていません。主要情報0%配当利回り-0.5%バイバック利回り総株主利回り-0.5%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向0%最近の配当と自社株買いの更新Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for $125 million worth of its shares.Nov 08すべての更新を表示Recent updatesInnoviva, Inc., Annual General Meeting, May 04, 2026Mar 25New major risk - Revenue and earnings growth Feb 26Full year 2025 earnings: EPS and revenues exceed analyst expectations Feb 26Price target decreased by 11% to US$32.25 Nov 20Innoviva's (NASDAQ:INVA) Solid Profits Have Weak FundamentalsNov 13Investor sentiment improves as stock rises 22% Nov 12Innoviva, Inc.'s (NASDAQ:INVA) Shares Bounce 26% But Its Business Still Trails The MarketNov 12Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for $125 million worth of its shares.Nov 08New minor risk - Shareholder dilution Nov 07Third quarter 2025 earnings: EPS and revenues exceed analyst expectations Nov 06Price target decreased by 10% to US$36.20 Oct 01We Think Innoviva (NASDAQ:INVA) Can Manage Its Debt With EaseSep 11Innoviva, Inc. Just Recorded A 54% EPS Beat: Here's What Analysts Are Forecasting NextAug 09Second quarter 2025 earnings: EPS and revenues exceed analyst expectations Aug 07Innoviva, Inc.'s (NASDAQ:INVA) Low P/S No Reason For ExcitementJun 23Innoviva: A Riddle Wrapped In A Mystery Inside An Enigma Jun 08First quarter 2025 earnings released: US$0.74 loss per share (vs US$0.58 profit in 1Q 2024) May 08Innoviva, Inc., Annual General Meeting, May 19, 2025Apr 09Full year 2024 earnings released: EPS: US$0.37 (vs US$2.75 in FY 2023) Feb 27Innoviva: Underappreciated Strength In Hospital Therapeutics Feb 23Innoviva, Inc.'s (NASDAQ:INVA) Popularity With Investors Is Under Threat From OverpricingDec 19Third quarter 2024 earnings released: EPS: US$0.019 (vs US$1.26 in 3Q 2023) Nov 07New minor risk - Earnings quality Nov 07Price target increased by 20% to US$18.00 Aug 06New minor risk - Financial position Aug 05Second quarter 2024 earnings released: US$0.56 loss per share (vs US$0.02 profit in 2Q 2023) Aug 01Benign Growth For Innoviva, Inc. (NASDAQ:INVA) Underpins Its Share PriceJul 26Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc. Appoints Patricia Drake as Chief Commercial OfficerJul 02New minor risk - Financial position Jun 23Innoviva: Potentially Overvalued Jun 21Now 21% undervalued May 28Why Innoviva's (NASDAQ:INVA) Shaky Earnings Are Just The Beginning Of Its ProblemsMay 21First quarter 2024 earnings released: EPS: US$0.58 (vs US$0.51 in 1Q 2023) May 09Innoviva, Inc., Annual General Meeting, Jun 17, 2024May 01Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.’s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024Apr 24Full year 2023 earnings released: EPS: US$2.75 (vs US$3.07 in FY 2022) Mar 01Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty TherapeuticsFeb 07Here's Why Innoviva (NASDAQ:INVA) Can Manage Its Debt ResponsiblyFeb 05Chief Accounting Officer & Secretary recently sold US$154k worth of stock Nov 19Is Innoviva (NASDAQ:INVA) A Risky Investment?Nov 04Third quarter 2023 earnings released: EPS: US$1.26 (vs US$3.81 in 3Q 2022) Nov 02Innoviva, Inc. Appoints Stephen Basso as Chief Financial OfficerAug 26Innoviva Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Nasdaq’s Audit Committee Composition RequirementsAug 08New major risk - Financial position Aug 04Second quarter 2023 earnings released: EPS: US$0.02 (vs US$0.013 in 2Q 2022) Aug 04Innoviva, Inc. Announces Resignation of Deborah L. Birx as Member of the Board of Directors and Chair of the Audit CommitteeJul 12Price target decreased by 23% to US$13.00 Jun 03First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 11Price target decreased by 12% to US$15.17 Mar 03Innoviva (NASDAQ:INVA) Seems To Use Debt Quite SensiblyMar 02Full year 2022 earnings released: EPS: US$3.07 (vs US$3.24 in FY 2021) Mar 02Innoviva, Inc. Announces Appointment of Sapna Srivastava to the Board of DirectorsJan 05Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 10Innoviva Stock? Not Yet. Short Puts? Definitely. Sep 19Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?Sep 19Price target decreased to US$18.67 Jul 20Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?Jun 16Continuing To Avoid Innoviva Inc. Jun 07First quarter 2022 earnings released: EPS: US$0.23 (vs US$0.93 in 1Q 2021) Apr 29Price target increased to US$20.50 Apr 12We Think Innoviva (NASDAQ:INVA) Can Manage Its Debt With EaseMar 04Taking Innoviva Winnings Off The Table, Again Feb 21Investor sentiment improved over the past week Feb 16Innoviva Inc.: Short Puts Are Compelling Jan 15Is Innoviva (NASDAQ:INVA) A Risky Investment?Oct 19Taking Profits In Innoviva Inc. Oct 16Independent Chairman of the Board recently bought US$264k worth of stock May 27First quarter 2021 earnings released: EPS US$0.93 (vs US$0.65 in 1Q 2020) May 01These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt SafelyMar 30Is Weakness In Innoviva, Inc. (NASDAQ:INVA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?Mar 04Full year 2020 earnings released: EPS US$2.22 (vs US$1.56 in FY 2019) Feb 28Revenue beats expectations Feb 28Full year 2020 earnings released: EPS US$2.21 (vs US$1.56 in FY 2019) Feb 05Revenue beats expectations Feb 05Did Innoviva's (NASDAQ:INVA) Share Price Deserve to Gain 36%?Jan 15New 90-day high: US$12.51 Jan 05These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt SafelyDec 25Investor sentiment improved over the past week Dec 17New 90-day high: US$11.81 Dec 16Will Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Prove Temporary Given Strong Fundamentals?Dec 04Third quarter earnings released Oct 30New 90-day low: US$9.99 Oct 16New 90-day low: US$10.85 Sep 24決済の安定と成長配当データの取得安定した配当: INVAの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: INVAの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Innoviva 配当利回り対市場INVA 配当利回りは市場と比べてどうか?セグメント配当利回り会社 (INVA)0%市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Pharmaceuticals)2.2%アナリスト予想 (INVA) (最長3年)n/a注目すべき配当: INVAは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: INVAは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: INVA US市場において目立った配当金を支払っていません。株主配当金キャッシュフローカバレッジ: INVAが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日(UTC時間)企業分析2026/05/04 18:48終値2026/05/01 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Innoviva, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18 アナリスト機関Jon LangenfeldBairdJames BirchenoughBarclaysPatrick TrucchioBerenberg15 その他のアナリストを表示
Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for $125 million worth of its shares.Nov 08
Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for $125 million worth of its shares.Nov 08
Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc. Appoints Patricia Drake as Chief Commercial OfficerJul 02
Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.’s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024Apr 24
Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty TherapeuticsFeb 07
Innoviva Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Nasdaq’s Audit Committee Composition RequirementsAug 08
Innoviva, Inc. Announces Resignation of Deborah L. Birx as Member of the Board of Directors and Chair of the Audit CommitteeJul 12
Is Weakness In Innoviva, Inc. (NASDAQ:INVA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?Mar 04
Will Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Prove Temporary Given Strong Fundamentals?Dec 04